Anthera Pharmaceuticals Stock Price To Earnings To Growth
| ANTHDelisted Stock | USD 0.0001 0.00 0.00% |
Anthera Pharmaceuticals fundamentals help investors to digest information that contributes to Anthera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anthera Pink Sheet. The fundamental analysis module provides a way to measure Anthera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anthera Pharmaceuticals pink sheet.
Anthera |
Anthera Pharmaceuticals Company Price To Earnings To Growth Analysis
Anthera Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Anthera Pharmaceuticals Price To Earnings To Growth | (0.05) X |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Anthera Pharmaceuticals has a Price To Earnings To Growth of -0.05 times. This is 107.04% lower than that of the Biotechnology sector and 101.59% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 101.02% higher than that of the company.
Anthera Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Anthera Fundamentals
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) | ||||
| Cash And Equivalents | 8.09 M | ||||
| Cash Per Share | 0.31 X | ||||
| Debt To Equity | 1.61 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (36.9 M) | ||||
| Short Ratio | 2.09 X | ||||
| Earnings Per Share | (1.76) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | -108.04 | ||||
| Market Capitalization | 617.83 K | ||||
| Total Asset | 3.67 M | ||||
| Retained Earnings | (436.8 M) | ||||
| Working Capital | 39.39 M | ||||
| Current Asset | 47.86 M | ||||
| Current Liabilities | 8.47 M | ||||
| Net Asset | 3.67 M |
About Anthera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anthera Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anthera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anthera Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |